What happened
Shares of the developmental vaccine and immunotherapy company Inovio Pharmaceuticals (NASDAQ: INO) fell by as much as 15.8% right out of the gate Thursday morning. This double-digit decline marks a sharp trend reversal for the small-cap biotech.
Following an investor presentation last Monday, Inovio’s shares jumped by a remarkable 83.7% over the first three trading days of the week. Investors seemingly piled into this biotech stock this week in the hopes of getting in before the company lands a large grant for its COVID-19 vaccine candidate, INO-4800.
Inovio’s shares have battled back from this rough start to Thursday’s trading session, but they are still down by 5.4% as of 10 a.m. EDT.
Image source: Getty Images.
So what
Not everyone was impressed by Inovio’s investor presentation, however. Ahead of the opening bell today, Roth Capital analyst Jonathan Aschoff reaffirmed his sell rating and $11 price target on the biotech’s stock. Aschoff, in effect, is calling for a hefty 40% correction relative to where Inovio’s shares closed on Wednesday. This bearish call appears to be the catalyst that sent the biotech’s stock spiraling downward in early morning action today.
In his note, Aschoff said INO-4800 “has virtually no chance” of winning out in a crowded field of competitors. He also said Inovio’s late-stage HPV cancer vaccine candidate, VGX-3100, is “destined to be a commercial failure.” That’s a bearish take on the biotech’s top two clinical candidates to be sure. As such, it’s not surprising to see Inovio’s shares taking a breather from their recent rally.
Now what
Should Inovio shareholders take Aschoff’s comments to heart? Clinical-stage biopharma stocks are always a risky investment — and Inovio’s shareholders would be wise to keep that in mind. Failure can occur at myriad steps during product development and commercialization, after all. But that doesn’t mean that anyone has a surefire take on the future of Inovio’s pipeline. In other words, investors probably shouldn’t overreact to this bearish call.
10 stocks we like better than Inovio Pharmaceuticals
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now… and Inovio Pharmaceuticals wasn’t one of them! That’s right — they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of August 1, 2020
George Budwell has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
